A Phase Ib/II, Mulicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 04 Jul 2019
At a glance
- Drugs Encorafenib (Primary) ; Ribociclib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 27 Jul 2016 Status changed from completed to discontinued.
- 22 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 15 Oct 2014 Planned End Date changed from 1 Jan 2016 to 1 Feb 2016, as per ClinicalTrials.gov record.